NCT04382339View on ClinicalTrials.gov

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/RBV/PegINFα-2

SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C

All Listed Sponsors

lead

Beni-Suef University

OTHER

NCT04382339 - Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 | Biotech Hunter | Biotech Hunter